Metastatic Renal Cell Carcinoma: Causes, Symptoms & Treatment

Metastatic renal cell carcinoma, also known as advanced kidney cancer, occurs when cancer cells from the kidney spread to other parts of the body. This type of cancer typically originates in the small tubes of the kidney responsible for filtering blood and removing waste products. The exact cause of metastatic renal cell carcinoma is not fully understood, but certain risk factors such as smoking, obesity, and high blood pressure may increase the likelihood of developing this condition.

Additionally, genetic factors and exposure to certain chemicals or medications may also play a role in the development of this disease. Understanding the nature of metastatic renal cell carcinoma and its potential causes can help individuals make informed decisions about their health and well-being.

What Are the Symptoms of Metastatic Renal Cell Carcinoma

Metastatic renal cell carcinoma can cause a variety of symptoms that may include blood in the urine, persistent pain in the back or side, unexplained weight loss, fatigue, fever, and swelling in the legs or ankles. Some patients may also experience a lump in the abdomen, loss of appetite, and anemia. It's important to consult with a healthcare provider if you notice any of these symptoms, as early detection and treatment are crucial for managing the condition effectively.

Blood in urine, also known as hematuria, is a common symptom of metastatic renal cell carcinoma.
Persistent back pain, often on one side, can be a sign of advanced kidney cancer spreading.
Unexplained weight loss, fatigue, and loss of appetite are potential indicators of metastatic renal cell carcinoma.
Swelling in the legs and ankles may occur due to kidney cancer affecting the lymphatic system.
Shortness of breath and coughing up blood can result from renal cell carcinoma metastasizing to the lungs.

Get a second opinion from trusted experts and makeconfident, informed decisions.

Get Second Opinion

Causes of Metastatic Renal Cell Carcinoma

The main factors contributing to this aggressive progression include the tumor's ability to invade nearby tissues and blood vessels, facilitating the cancer cells' access to the bloodstream and lymphatic system for dissemination. Additionally, renal cell carcinoma can exhibit resistance to conventional treatments, allowing it to persist and metastasize. Genetic mutations and abnormal signaling pathways also play a crucial role in promoting the metastatic potential of renal cell carcinoma.

Metastatic renal cell carcinoma can result from the spread of cancer cells to distant organs such as the lungs or bones.
Chronic smoking and exposure to environmental toxins are significant risk factors for the development of metastatic renal cell carcinoma.
Genetic factors, such as mutations in genes like VHL or PBRM1, can predispose individuals to metastatic renal cell carcinoma.
Patients with a history of hereditary conditions like von Hippel-Lindau (VHL) disease have an increased risk of developing metastatic renal cell carcinoma.
Obesity and a diet high in processed foods and saturated fats may contribute to the progression of renal cell carcinoma to a metastatic stage.

Types Of Metastatic Renal Cell Carcinoma

Clear cell RCC is the most common type, accounting for about 70-75% of cases, characterized by clear cytoplasm due to lipid and glycogen content. Papillary RCC comprises 10-15% of cases and is categorized into type 1 and type 2 based on histologic features.

Chromophobe RCC is less common, accounting for 5-10% of cases, and has unique morphological and genetic characteristics. The unclassified subtype encompasses a small percentage of cases with features that do not fit into the other categories.

Clear cell renal cell carcinoma is the most common type of metastatic renal cell carcinoma.
Papillary renal cell carcinoma accounts for around 10-15% of metastatic cases.
Chromophobe renal cell carcinoma is a less common subtype but can also metastasize.
Collecting duct renal cell carcinoma is a rare and aggressive form of metastatic renal cell carcinoma.
Renal medullary carcinoma is a rare subtype associated with sickle cell trait and predominantly affects young individuals.
Translocation renal cell carcinoma is a rare subtype characterized by genetic translocations.
Oncocytoma, while typically benign, can rarely metastasize and should be considered in the differential diagnosis of metastatic renal cell carcinoma.

Risk Factors

Metastatic renal cell carcinoma, a type of kidney cancer that has spread beyond the kidneys, can be influenced by various risk factors. These include older age, smoking, obesity, high blood pressure, and a family history of kidney cancer. Additionally, individuals with certain genetic conditions, such as von Hippel-Lindau disease or hereditary papillary renal cell carcinoma, may have an increased risk of developing metastatic renal cell carcinoma. Understanding these risk factors is crucial in identifying individuals who may benefit from closer monitoring or preventive measures to manage this aggressive form of cancer.

Smoking is a significant risk factor for developing metastatic renal cell carcinoma, increasing the likelihood of cancer spreading to other parts of the body.
Obesity has been linked to a higher risk of metastatic renal cell carcinoma, as excess body weight can contribute to the progression of the disease.
High blood pressure, especially when uncontrolled, is a risk factor for metastatic renal cell carcinoma, potentially promoting the spread of cancer cells.
Family history of kidney cancer can elevate the risk of developing metastatic renal cell carcinoma, indicating a genetic predisposition to the disease.
Exposure to certain chemicals or environmental toxins may increase the risk of metastatic renal cell carcinoma, highlighting the importance of occupational and environmental safety measures.

Your health is everything - prioritize your well-being today.

Schedule Your Appointment

Diagnosis of Metastatic Renal Cell Carcinoma

Imaging techniques such as CT scans, MRIs, and bone scans are used to identify the presence and extent of metastases. Blood tests may reveal elevated levels of certain markers, such as lactate dehydrogenase (LDH) or alkaline phosphatase, which can indicate disease progression. In some cases, a biopsy of the affected tissue may be necessary to confirm the presence of metastatic renal cell carcinoma. The process of diagnosis is crucial in determining the appropriate treatment plan and prognosis for individuals with this advanced stage of kidney cancer.

Imaging studies like CT scans and MRIs are commonly used to detect metastases in patients with renal cell carcinoma.
Biopsy of suspicious lesions may be performed to confirm the presence of metastatic renal cell carcinoma.
Blood tests such as liver function tests and tumor markers can provide additional information in diagnosing metastatic renal cell carcinoma.
A thorough medical history and physical examination are essential steps in the diagnostic workup for metastatic renal cell carcinoma.

Treatment for Metastatic Renal Cell Carcinoma

Treatment options for metastatic renal cell carcinoma typically involve a multidisciplinary approach tailored to each patient's specific needs. Commonly used therapies include targeted therapies that inhibit specific pathways involved in cancer growth and spread, immunotherapy to enhance the immune system's ability to recognize and attack cancer cells, and systemic treatments like chemotherapy for more aggressive cases. Additionally, surgical interventions may be considered to remove tumors or affected organs. Clinical trials are also available for eligible patients to access cutting-edge treatments. The choice of treatment depends on factors such as the extent of the disease, overall health status, and individual preferences, with the goal of improving quality of life and extending survival.

Surgery may be considered to remove the primary tumor and any metastases that are confined to specific areas, aiming to alleviate symptoms and potentially prolong survival.
Systemic therapies such as targeted therapy and immunotherapy are commonly used to target specific pathways in cancer cells or boost the body's immune response against the cancer.
Radiation therapy can be utilized to relieve symptoms and manage pain in metastatic renal cell carcinoma by targeting specific areas of the body where the cancer has spread.
Clinical trials offer access to innovative treatments that are still under investigation, providing patients with the opportunity to receive cutting-edge therapies.
Palliative care focuses on improving the quality of life for patients with metastatic renal cell carcinoma by addressing symptoms, psychological support, and